Screener
Allogene Therapeutics ALLO Other operating expenses
Discontinued — last reported Q1 '26
Other operating expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $32,003 | $50,200 |
| General and administrative | 14,089 | 14,991 |
| Total operating expenses | 46,092 | 65,191 |
| Loss from operations | (46,092) | (65,191) |
| Other income (expenses), net: | ||
| Interest and other income, net | 3,573 | 5,516 |
| Interest expense | (300) | (150) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's other operating expenses?
- Allogene Therapeutics (ALLO) reported other operating expenses of $46.09M in Q1 2026.
- How has Allogene Therapeutics's other operating expenses changed year-over-year?
- Allogene Therapeutics's other operating expenses decreased by 29.3% year-over-year, from $65.19M to $46.09M.
- What is the long-term trend for Allogene Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Allogene Therapeutics's other operating expenses has grown at a -8.2% compound annual growth rate (CAGR), from $294.28M to $209.32M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Allogene Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude